Your session is about to expire
← Back to Search
Bendamustine + Obinutuzumab for Mantle Cell Lymphoma
Study Summary
This trial is testing a new chemotherapy treatment for people with a certain type of cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 229 Patients • NCT02264574Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Bendamustine + Obinutuzumab (BO)
Frequently Asked Questions
Are we still recruiting participants for this experiment?
"That is accurate. As of 9/13/2022, the clinical trial posted on 10/19/2017 was still edited and looking for 32 participants at 1 site."
What is the existing research on Obinutuzumab?
"173 Obinutuzumab trials are currently active with 36 of those in Phase 3. Most of the Plymouth, Indiana based trials for Obinutuzumab are running out, however there are 9502 locations globally conducting similar research."
How many subjects are currently enrolled in this research project?
"That is accurate. According to the listing on clinicaltrials.gov, this study is still looking for subjects. This trial was first advertised on October 19th, 2017 and received its last update on September 13th, 2020. The research team needs 32 individuals from 1 location."
What is the main purpose of Obinutuzumab?
"cancers including refractory mantle cell lymphoma, refractory follicular lymphoma, and chronic lymphocytic leukemia (cll) may be responsive to Obinutuzumab treatment."
When was Obinutuzumab cleared by the FDA?
"Obinutuzumab falls into the Phase 2 category, meaning that while there is evidence of its safety, there is none yet to support efficacy. Therefore, it was given a score of 2."
Share this study with friends
Copy Link
Messenger